New hope for arthritis sufferers? CIT-013 drug trial begins

NCT ID NCT06567470

Recruiting now Disease control Sponsor: Citryll BV Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called CIT-013 in 88 adults with moderately active rheumatoid arthritis. Participants will receive either CIT-013 or a placebo every two weeks for six weeks. The goal is to see if CIT-013 reduces joint swelling and pain better than a placebo, and to check for any side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS

Contacts and locations

Locations

BE-02
WITHDRAWN

Antwerp, Belgium
DE-01
RECRUITING

München, Germany
DE-02
RECRUITING

München, Germany
DE-03
WITHDRAWN

Ratingen, Germany
DE-04
RECRUITING

Bamberg, Germany
DE-05
RECRUITING

Berlin, Germany
ES-01
RECRUITING

Santander, Spain
ES-02
RECRUITING

A Coruña, Spain
ES-03
RECRUITING

Santiago de Compostela, Spain
ES-04
RECRUITING

Barcelona, Spain
ES-05
RECRUITING

Barcelona, Spain
ES-06
RECRUITING

Madrid, Spain
NL-01
RECRUITING

Rotterdam, Netherlands
NL-02
WITHDRAWN

Amsterdam, Netherlands
NL-03
NOT_YET_RECRUITING

Nijmegen, Netherlands
NL-04
WITHDRAWN

Leiden, Netherlands
NL-05
RECRUITING

Leeuwarden, Netherlands
PL-01
RECRUITING

Bialystok, Poland
PL-02
RECRUITING

Poznan, Poland
PL-03
RECRUITING

Lublin, Poland
PL-04
RECRUITING

Warsaw, Poland
PL-05
RECRUITING

Torun, Poland
PL-07
RECRUITING

Krakow, Poland
Site BE-01
RECRUITING

Leuven, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.